Arvo, a Brazilian company applying artificial intelligence to healthcare payments, announced a USD 20 million (BRL 106 million) Series A on 17 September 2025, co-led by Kaszek and Base10 Partners with Canary and K50 Ventures. It matters because the capital goes into the payments layer between hospitals and insurers, where how much and when a provider gets paid is decided, and because two top-tier funds are sharing the lead.
The transaction
- Company. Arvo, founded in 2022. It builds artificial-intelligence and machine-learning tools to validate billing, audit claims and authorise procedures between healthcare providers and payers.
- Instrument and amount. Series A of USD 20 million, BRL 106 million. Valuation not disclosed.
- Investors. Kaszek and Base10 Partners as co-leads; Canary and K50 Ventures, which had already invested BRL 25 million in the previous round in September 2024.
- Use of proceeds. Expand operations, strengthen transaction-processing infrastructure, launch new products and hire data-science and engineering talent; explore strategic acquisitions (LatamList).
- Team. In October 2025 the company appointed Bernard Texeire as vice-president of revenue, from Falconi and Coru, and David Robert as chief technology officer, formerly CTO of Elo7 and vice-president of engineering at Loft (Startups.com.br).
- Status. Closed.
Value drivers
Processed volume. More than USD 25 billion in healthcare claims have gone through the platform. In our reading, that volume is the asset that trains the models and the one a competitor cannot replicate with capital.
Verifiable growth. Revenue and clients grew fourfold in a year (LatamList). At that pace, the Series A funds infrastructure to sustain scale, not the search for a product.
Measurable client return. The tools raise auditing and billing productivity by an average of 25% within six months of adoption. The client can calculate the return on investment before signing, which shortens the sales cycle.
Position in the payment flow. Whoever validates the claim before payment accumulates data from both sides of the table. In our reading, that position creates high switching costs and explains why the company is already considering acquisitions.
Competition for the deal. Two funds co-leading and prior investors following on suggest, in our reading, a process with more than one term sheet on the table.
What the market is signalling
For Mexico the parallel lies in major medical expense insurance, where GNP Seguros holds more than 24% of the segment and has just taken a stake in Meddi to bring a physical-digital model to its policyholders. The claim between hospital and insurer is still a manual process across much of the Mexican market, and a company that automates it with measured results has pricing comparables in Arvo and natural buyers among insurers, hospital groups and claims administrators.
For a founder, the reading is that international capital enters healthcare-payments infrastructure when there is processed volume and demonstrable return, not promise. For a Mexican buyer, the fact that Arvo is exploring acquisitions opens a regional exit route for companies with claims data and institutional clients. For a lender, a model with recurring revenue from payers can support venture debt after the Series A.
G2’s reading for a mandate
Preparing a round in this layer should centre on three auditable figures: volume of claims processed, productivity improvement measured at clients, and net revenue retention. An investment committee will compare those metrics with Arvo’s and ask for a product plan that justifies the infrastructure spend. If the company could be a regional acquisition target, it pays to design the process to receive fund term sheets and a strategic-buyer approach in parallel.
Sources
- LatamList (17 September 2025): Arvo raises $20M Series A to expand healthcare payments AI in Brazil
- Startups.com.br (9 October 2025): Arvo traz novo vice-presidente de revenue e CTO
- El Financiero (11 March 2026): GNP invierte 137 mdp en Meddi